Teva closes in on $3B cost-cutting goal by Eric Sagonowsky Thursday, May 2, 2019 So far in Teva's extensive cost-cutting drive, 10,000 people have left the company, CEO Kåre Schultz said Thursday.
Where's Mylan planning to put its ramped-up 2019 spending? by Carly Helfand Wednesday, February 27, 2019 Mylan is in the midst of rolling out several key drugs, so extra spend might be warranted. But analysts worry whether that outlay will pay off.
Teva forecasts tough year as generics hammer Copaxone by Arlene Weintraub Wednesday, February 13, 2019 Teva's Copaxone is losing ground to generic competition—and the company's newer drugs aren’t taking off fast enough to make up for the loss.
Mylan's generic Advair discount not as big as it looks: analysts by Carly Helfand Wednesday, February 13, 2019 Mylan has set its list price for its Advair copy at a 70% discount to the brand. But the move may not be as dramatic as it seems.
Rebounding Teva is ‘too cheap to ignore,' upbeat analysts say by Angus Liu Friday, February 8, 2019 What kind of difference can one year make? Just ask some Teva analysts, who are upbeat that the drugmaker's cost-cutting measures are paying off.
Teva hit with $6.3M retaliation verdict in ex-staffer's lawsuit by Eric Sagonowsky Monday, December 3, 2018 A judge ruled that Teva must face a lawsuit alleging employment discrimination in September, and now jurors ordered the company to pay $6.3 million.
Teva’s sunny forecast for migraine drug raises eyebrows by Arlene Weintraub Thursday, November 1, 2018 Concerns about discounting on Teva's migraine drug Ajovy are high as the company's generics unit and MS blockbuster falter.
Teva's Copaxone patent loss gives generics free rein by Eric Sagonowsky Monday, October 15, 2018 Teva lost a patent appeal for multiple sclerosis blockbuster Copaxone, a drug that has seen a considerable sales decline due to generics.
Novartis' Gilenya tops Teva's Copaxone in head-to-head MS study by Carly Helfand Thursday, October 11, 2018 Teva’s Copaxone has hung on to market share even in the face of oral competitors and generics. But Novartis aims to change that.
Teva eases debt burden with $400M tender offer by Arlene Weintraub Friday, September 7, 2018 Teva is cutting its debt load, but a successful turnaround rests on its new products and late-stage pipeline, analysts say.
